Effect study of low-dose roxadustat combined with rHuEPO in the treatment of patients with renal anemia and maintenance hemodialysis for chronic renal failure with poor efficacy of rHuEPO alone
Objective To explore the effect of low-dose roxadustat combined with recombinant human erythropoietin(rHuEPO)in the treatment of patients with renal anemia(RA)and maintenance hemodialysis(MHD)for chronic renal failure(CRF)with poor efficacy of rHuEPO alone.Methods A total of 100 cases of CRF MHD RA patients with poor efficacy of rHuEPO alone were randomly divided into a control group(n=50)and an observation group(n=50).The control group was treated with rHuEPO+polysaccharide iron complex,and the observation group was treated with low-dose roxadustat capsules on the basis of the control group.The therapeutic effect,anemia recovery indicators,microinflammatory indicators and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 98.00%,which was higher than 84.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the hemoglobin of the observation group was(131.26±9.77)g/L,the hematocrit was(48.50±5.28)%,the erythropoietin(EPO)was(22.39±3.48)U/L,the ferritin was(587.85±28.36)μg/L and the transferrin was(2.83±0.74)g/L,which were higher than(113.42±8.65)g/L,(36.46±5.07)%,(15.18±3.11)U/L,(425.31±26.64)μg/L and(1.96±0.41)g/L of the control group;the C-reactive protein and β2 microglobulin of the observation group were(10.34±2.18)mg/L(10.69±2.74)mg/L,which were lower than(13.87±2.67)and(14.87±3.12)mg/L of the control group;the difference was statistically significant(P<0.05).There was no significant difference in erythrocyte sedimentation rate between the two groups after treatment(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Low-dose roxadustat combined with rHuEPO is effective in treating patients with CRF MHD RA who have poor efficacy of rHuEPO alone,which can effectively improve patients'anemia symptoms and reduce serum microinflammatory indicators,and has a high safety profile.
RoxadustatRecombinant human erythropoietinMaintenance hemodialysisRenal anemia
NETL
NSTL
万方数据
